Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CFTR Gene Mutation”

67 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 67 results

Not applicableApproved For MarketingNCT04058210
What this trial is testing

VX-445/TEZ/IVA Expanded Access Program for Cystic Fibrosis (CF) Patients Heterozygous for F508del Mutation and a Minimal Function Mutation (F/MF Genotypes)

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
Large-scale testing (Phase 3)Study completedNCT01897233
What this trial is testing

Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 62
Large-scale testing (Phase 3)Study completedNCT01807923
What this trial is testing

Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation

Who this might be right for
Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Vertex Pharmaceuticals Incorporated 559
Not applicableStudy completedNCT02807415
What this trial is testing

ICM to Evaluate the Activation of p.Phe508del-CFTR by Lumacaftor in Combination With Ivacaftor

Who this might be right for
Cystic Fibrosis
Hannover Medical School 104
Post-approval studies (Phase 4)Study completedNCT07632768
What this trial is testing

Safety of Stopping Pancreatic Enzyme Replacement Therapy in Children With Improved Pancreatic Function After Highly Effective Modulator Therapy

Who this might be right for
Cystic Fibrosis (CF)Pancreatic InsufficiencyPancreas Disease+3 more
Indiana University 17
Testing effectiveness (Phase 2)Study completedNCT02709109
What this trial is testing

Evaluate the Safety and Efficacy of VX-371 in Subjects With Cystic Fibrosis Who Are Homozygous for the F508del-CFTR Mutation

Who this might be right for
Cystic Fibrosis
Parion Sciences 147
Large-scale testing (Phase 3)Ended earlyNCT02742519
What this trial is testing

Evaluate Efficacy and Safety of Ivacaftor in Subjects With Cystic Fibrosis Aged 3 Through 5 Years Who Have a Specified CFTR Gating Mutation

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 14
Testing effectiveness (Phase 2)Study completedNCT00457821
What this trial is testing

Safety Study of Ivacaftor in Subjects With Cystic Fibrosis

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 39
Post-approval studies (Phase 4)Ended earlyNCT02823470
What this trial is testing

A Pilot Study to Evaluate the Use of Smart Adherence Technology to Measure Lumacaftor/Ivacaftor Adherence in CF Subjects Homozygous for the F508del CFTR Mutation

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 24
Early research (Phase 1)Study completedNCT03093714
What this trial is testing

Evaluate Safety, PK and PD of FDL169 in Cystic Fibrosis Subjects

Who this might be right for
Cystic Fibrosis
Flatley Discovery Lab LLC 27
Large-scale testing (Phase 3)Study completedNCT01931839
What this trial is testing

Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis

Who this might be right for
Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Vertex Pharmaceuticals Incorporated 1,164
Large-scale testing (Phase 3)Study completedNCT02725567
What this trial is testing

Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Ivacaftor in Subjects With Cystic Fibrosis Who Are Less Than 24 Months of Age and Have an Ivacaftor-Responsive CFTR Mutation

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 57
Testing effectiveness (Phase 2)Study completedNCT02589236
What this trial is testing

Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation

Who this might be right for
Cystic Fibrosis
Nivalis Therapeutics, Inc. 138
Large-scale testing (Phase 3)Study completedNCT02392234
What this trial is testing

Evaluate the Efficacy and Safety of Ivacaftor and VX-661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Heterozygous for the F508del-cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Mutation

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 248
Post-approval studies (Phase 4)Study completedNCT02875366
What this trial is testing

The Effects of Lumacaftor/Ivacaftor (LUM/IVA) on Exercise Tolerance in Subjects With Cystic Fibrosis (CF), Homozygous for the F508del-CFTR Mutation

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 70
Testing effectiveness (Phase 2)Study completedNCT03045523
What this trial is testing

Evaluate GLPG2222 in Ivacaftor-treated Subjects With Cystic Fibrosis

Who this might be right for
Cystic Fibrosis
Lakefront Biotherapeutics NV 37
Testing effectiveness (Phase 2)Study completedNCT02070744
What this trial is testing

Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 40
Testing effectiveness (Phase 2)Study completedNCT01225211
What this trial is testing

Study of VX-809 Alone and in Combination With VX-770 in Cystic Fibrosis (CF) Patients Homozygous or Heterozygous for the F508del-CFTR Mutation

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 312
Large-scale testing (Phase 3)Study completedNCT03559062
What this trial is testing

Evaluate Efficacy and Safety of TEZ/IVA in Subjects Aged 6 Through 11 Years With Cystic Fibrosis

Who this might be right for
Cystic Fibrosis
Vertex Pharmaceuticals Incorporated 67
Early research (Phase 1)Study completedNCT01746784
What this trial is testing

Safety and Pharmacokinetic Study of N6022 in Subjects With Cystic Fibrosis Homozygous for the F508del-CFTR Mutation

Who this might be right for
Cystic Fibrosis
Nivalis Therapeutics, Inc. 66
Next Page